Promising drug targets HER2 cancers in new trial
NCT ID NCT07192068
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 47 times
Summary
This phase 2 trial tests zanidatamab, a drug that targets cancer cells with a HER2 gene alteration, in 105 adults with advanced lung, endometrial, colorectal, head & neck, or sarcoma cancers. Participants receive the drug every 3 weeks, and doctors monitor tumor shrinkage and side effects. The goal is to see if zanidatamab can shrink or stabilize these tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Chu Timone
RECRUITINGMarseille, France
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Gustave Roussy
RECRUITINGVillejuif, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut de Cancérologie de Lorraine
ACTIVE_NOT_RECRUITINGVandœuvre-lès-Nancy, France
-
Institut de Cancérologie de l'Ouest
ACTIVE_NOT_RECRUITINGAngers, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zanidatamab
What this could lead to
If successful, this could offer a new treatment option for several hard-to-treat cancers that have a specific HER2 gene change.
What could go wrong
This is a mid-stage trial with only 105 participants, so results may not apply to everyone. Zanidatamab can cause side effects, and not all patients may see tumor shrinkage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.